Lytix Biopharma AS (LYTIX) - Total Liabilities
Based on the latest financial reports, Lytix Biopharma AS (LYTIX) has total liabilities worth Nkr19.77 Million NOK (≈ $2.08 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Lytix Biopharma AS (LYTIX) cash conversion ratio to assess how effectively this company generates cash.
Lytix Biopharma AS - Total Liabilities Trend (2017–2025)
This chart illustrates how Lytix Biopharma AS's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Lytix Biopharma AS's assets to evaluate the company's liquid asset resilience ratio.
Lytix Biopharma AS Competitors by Total Liabilities
The table below lists competitors of Lytix Biopharma AS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Toma as
PR:TOMA
|
Czech Republic | Kč1.04 Billion |
|
AGF A/S
CO:AGF-B
|
Denmark | Dkr85.39 Million |
|
Agrify Corp
NASDAQ:AGFY
|
USA | $103.43 Million |
|
Embellence Group AB
ST:EMBELL
|
Sweden | Skr248.00 Million |
|
Silvercrest Asset Management Group Inc
NASDAQ:SAMG
|
USA | $81.72 Million |
|
Ardea Resources Ltd
AU:ARL
|
Australia | AU$28.99 Million |
|
Hun Yenilenebilir Enerji Uretim AS
IS:HUNER
|
Turkey | TL3.96 Billion |
|
Kjell Group AB
ST:KJELL
|
Sweden | Skr1.38 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Lytix Biopharma AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see LYTIX company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.57 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lytix Biopharma AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lytix Biopharma AS (2017–2025)
The table below shows the annual total liabilities of Lytix Biopharma AS from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Nkr19.77 Million ≈ $2.08 Million |
-48.83% |
| 2024-12-31 | Nkr38.64 Million ≈ $4.07 Million |
+207.77% |
| 2023-12-31 | Nkr12.55 Million ≈ $1.32 Million |
-25.67% |
| 2022-12-31 | Nkr16.89 Million ≈ $1.78 Million |
+26.64% |
| 2021-12-31 | Nkr13.34 Million ≈ $1.40 Million |
+4.79% |
| 2020-12-31 | Nkr12.73 Million ≈ $1.34 Million |
+230.25% |
| 2019-12-31 | Nkr3.85 Million ≈ $405.55K |
-78.41% |
| 2018-12-31 | Nkr17.85 Million ≈ $1.88 Million |
-49.44% |
| 2017-12-31 | Nkr35.30 Million ≈ $3.71 Million |
-- |
About Lytix Biopharma AS
Lytix Biopharma AS, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, which is in Phase II clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma. The company also offers LTX-401, an oncolytic… Read more